Prognostic impact of thymidine phosphorylase expression in breast cancer - Comparison of microarray and immunohistochemical data

European Journal of Cancer

Volumn 46, Issue 3, 2010, Pages 549-557

  Ruckhaberle E ^a   Karn, T ^a   Engels, K ^a   Turley, H ^b   Hanker, L ^a   Muller V ^c   Schmidt, M ^d   Ahr, A ^a   Gaetje, R ^a   Holtrich, U ^a   Kaufmann, M ^a   Rody, A ^a  

^a GOETHE UNIVERSITY   (Germany)

^b JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^c UNIVERSITY OF HAMBURG   (Germany)

^d JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Breast cancer; Immunohistochemistry; Microarray; Prognosis; Thymidine phosphorylase

Indexed keywords

BIOLOGICAL MARKER; MESSENGER RNA; THYMIDINE PHOSPHORYLASE;

ARTICLE; BREAST CANCER; CONTROLLED STUDY; DISEASE FREE SURVIVAL; ENZYME PHOSPHORYLATION; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; INTERFERON INDUCTION; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; GENE EXPRESSION PROFILING; HUMANS; IMMUNOENZYME TECHNIQUES; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; RNA, MESSENGER; RNA, NEOPLASM; SURVIVAL ANALYSIS; THYMIDINE PHOSPHORYLASE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 75149187415     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2009.11.020     Document Type: Article

References (51)

1. Bronckaers A, Gago F, Balzarini J, Liekens S. The dual role of thymidine phosphorylase in cancer development and chemotherapy. Med Res Rev 2009 [epub ahead of print].
2. Takebayashi Y., Yamada K., Miyadera K., et al. The activity and expression of thymidine phosphorylase in human solid tumours. Eur J Cancer 32A (1996) 1227-1232
3. Koopman M., Venderbosch S., Nagtegaal I.D., van Krieken J.H., and Punt C.J. A review on the use of molecular markers of cytotoxic therapy for colorectal cancer, what have we learned?. Eur J Cancer 45 11 (2009) 1935-1949
4. Cao D., Russell R.L., Zhang D., Leffert J.J., and Pizzorno G. Uridine phosphorylase (-/-) murine embryonic stem cells clarify the key role of this enzyme in the regulation of the pyrimidine salvage pathway and in the activation of fluoropyrimidines. Cancer Res 62 8 (2002) 2313-2317
5. Schüller J., Cassidy J., Dumont E., et al. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol 45 4 (2000) 291-297
6. Meropol N.J., Gold P.J., Diasio R.B., et al. Thymidine phosphorylase expression is associated with response to capecitabine plus irinotecan in patients with metastatic colorectal cancer. J Clin Oncol 24 25 (2006) 4069-4077
7. Layman R.M., Thomas D.G., Griffith K.A., et al. Neoadjuvant docetaxel and capecitabine and the use of thymidine phosphorylase as a predictive biomarker in breast cancer. Clin Cancer Res 13 14 (2007) 4092-4097
8. Puglisi F., Cardellino G.G., Crivellari D., et al. Thymidine phosphorylase expression is associated with time to progression in patients receiving low-dose, docetaxel-modulated capecitabine for metastatic breast cancer. Ann Oncol 19 9 (2008) 1541-1546
9. Andreetta C., Puppin C., Minisini A., et al. Thymidine phosphorylase expression and benefit from capecitabine in patients with advanced breast cancer. Ann Oncol 20 2 (2009) 265-271
10. Koopman M., Venderbosch S., van Tinteren H., et al. Predictive and prognostic markers for the outcome of chemotherapy in advanced colorectal cancer, a retrospective analysis of the phase III randomised CAIRO study. Eur J Cancer 45 11 (2009) 1999-2006
11. Fox S.B., Engels K., Comley M., et al. Relationship of elevated tumour thymidine phosphorylase in node-positive breast carcinomas to the effects of adjuvant CMF. Ann Oncol 8 3 (1997) 271-275
12. Yang Q., Barbareschi M., Mori I., et al. Prognostic value of thymidine phosphorylase expression in breast carcinoma. Int J Cancer 97 4 (2002) 512-517
13. Ioachim E. Thymidine phoshorylase expression in breast cancer: the prognostic significance and its association with other angiogenesis related proteins and extracellular matrix components. Histol Histopathol 23 2 (2008) 187-196
14. Relf M., LeJeune S., Scott P.A.E., et al. Expression of the angiogenic factor vascular endothelial cell growth factor, acidic and basic fibroblast growth factors, tumour growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res 57 (1997) 963-969
15. Li H., Suo Z., Zhang Y., et al. The prognostic significance of thymidine phosphorylase, thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expressions in breast carcinomas. Histol Histopathol 19 1 (2004) 129-136
16. Rody A., Holtrich U., Pusztai L., et al. T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers. Breast Cancer Res 11 2 (2009) R15
17. Miller L.D., Smeds J., George J., et al. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci USA 102 38 (2005) 13550-13555
18. Sotiriou C., Wirapati P., Loi S., et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 98 4 (2006) 262-272
19. Pawitan Y., Bjohle J., Amler L., et al. Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. Breast Cancer Res 7 6 (2005) R953-R964
20. Minn A.J., Gupta G.P., Siegel P.M., et al. Genes that mediate breast cancer metastasis to lung. Nature 436 7050 (2005) 518-524
21. Loi S., Haibe-Kains B., Desmedt C., et al. Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J Clin Oncol 25 10 (2007) 1239-1246
22. Wang Y., Klijn J.G., Zhang Y., et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365 9460 (2005) 671-679
23. Desmedt C., Piette F., Loi S., et al., TRANSBIG Consortium. Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin Cancer Res 13 11 (2007) 3207-3214
24. The International Genomics Consortium (IGC). The expO project (Expression Project for Oncology) .
25. Hess K.R., Anderson K., Symmans W.F., et al. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol 24 26 (2006) 4236-4244
26. Rody A., Holtrich U., Gaetje R., et al. Poor outcome in estrogen receptor-positive breast cancers predicted by loss of plexin B1. Clin Cancer Res 13 4 (2007) 1115-1122
27. Ahr A., Karn T., Solbach C., et al. Identification of high risk breast-cancer patients by gene expression profiling. Lancet 359 9301 (2002) 131-132
28. Rody A., Karn T., Solbach C., et al. The erbB2+ cluster of the intrinsic gene set predicts tumor response of breast cancer patients receiving neoadjuvant chemotherapy with docetaxel, doxorubicin and cyclophosphamide within the GEPARTRIO trial. Breast 16 3 (2007) 235-240
29. Karn T, Metzler D, Ruckhäberle E, et al. Data driven derivation of cutoffs from a pool of 3,030 Affymetrix arrays to stratify distinct clinical types of breast cancer. Breast Cancer Res Treat 2009 [epub ahead of print].
30. Chen DT, Nasir A, Culhane A, et al. Proliferative genes dominate malignancy-risk gene signature in histologically-normal breast tissue. Breast Cancer Res Treat 2009.
31. Ruckhäberle E., Rody A., Engels K., et al. Microarray analysis of altered sphingolipid metabolism reveals prognostic significance of sphingosine kinase 1 in breast cancer. Breast Cancer Res Treat 112 1 (2008) 41-52
32. Imazano Y., Takebayashi Y., Nishiyama K., et al. Correlation between thymidine phosphorylase expression and prognosis in human renal cell carcinoma. J Clin Oncol 15 7 (1997) 2570-2578
33. Koukourakis M.I., Giatromanolaki A., Kakolyris S., et al. Different patterns of stromal and cancer cell thymidine phosphorylase reactivity in non-small-cell lung cancer: impact on tumour neoangiogenesis and survival. Br J Cancer 77 10 (1998) 1696-1703
34. Takao S., Takebayashi Y., Che X., et al. Expression of thymidine phosphorylase is associated with a poor prognosis in patients with ductal adenocarcinoma of the pancreas. Clin Cancer Res 4 7 (1998) 1619-1624
35. van Triest B., Pinedo H.M., Blaauwgeers J.L., et al. Prognostic role of thymidylate synthase, thymidine phosphorylase/platelet-derived endothelial cell growth factor, and proliferation markers in colorectal cancer. Clin Cancer Res 6 3 (2000) 1063-1072
36. O'Byrne K.J., Koukourakis M.I., Giatromanolaki A., et al. Vascular endothelial growth factor, platelet-derived endothelial cell growth factor and angiogenesis in non-small-cell lung cancer. Br J Cancer 82 8 (2000) 1427-1432
37. Yasuno M., Mori T., Koike M., et al. Importance of thymidine phosphorylase expression in tumor stroma as a prognostic factor in patients with advanced colorectal carcinoma. Oncol Rep 13 3 (2005) 405-412
38. Sivridis E., Giatromanolaki A., Papadopoulos I., et al. Thymidine phosphorylase expression in normal, hyperplastic and neoplastic prostates: correlation with tumour associated macrophages, infiltrating lymphocytes, and angiogenesis. Br J Cancer 86 9 (2002) 1465-1471
39. Su A.I., Wiltshire T., Batalov S., et al. A gene atlas of the mouse and human protein-encoding transcriptomes. Proc Natl Acad Sci USA 101 16 (2004) 6062-6067
40. Berglund L., Björling E., Oksvold P., et al. A genecentric human protein atlas for expression profiles based on antibodies. Mol Cell Proteomics 10 (2008) 2019-2027
41. Kobayashi M., Sugimoto T., Okabayashi T., et al. Localization of thymidine phosphorylase in breast cancer tissue. Med Mol Morphol 38 (2005) 112-117
42. Toi M., Ueno T., Matsumoto H., et al. Significance of thymidine phosphorylase as a marker of protumor monocytes in breast cancer. Clin Cancer Res 5 5 (1999) 1131-1137
43. Saito S., Tsuno N., Nagawa H., et al. Expression of platelet-derived endothelial cell growth factor correlates with good prognosis in patients with colorectal carcinoma. Cancer 88 1 (2000) 42-49
44. Fox S.B., Moghaddam A., Westwood M., et al. Plateletderived endothelial cell growth factor/thymidine phosphorylase expression in normal tissues: An immunohistochemical study. J Pathol 176 (1995) 183-190
45. Yoshimura A., Kuwazuru Y., Furukawa T., et al. Purification and tissue distribution of human thymidine phosphorylase; high expression in lymphocytes, reticulocytes and tumors. Biochim Biophys Acta 1034 (1990) 107-113
46. Teschendorff A.E., Miremadi A., Pinder S.E., Ellis I.O., and Caldas C. An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer. Genome Biol 8 8 (2007) R157
47. Finak G., Bertos N., Pepin F., et al. Stromal gene expression predicts clinical outcome in breast cancer. Nat Med 14 5 (2008) 518-527
48. Calabrò A., Beissbarth T., Kuner R., et al. Effects of infiltrating lymphocytes and estrogen receptor on gene expression and prognosis in breast cancer. Breast Cancer Res Treat 116 1 (2009) 69-77
49. Schmidt M., Böhm D., von Törne C., et al. The humoral immune system has a key prognostic impact in node-negative breast cancer. Cancer Res 68 13 (2008) 5405-5413
50. Wirapati P., Sotiriou C., Kunkel S., et al. Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res 10 4 (2008) R65
51. Denkert C., Loibl S., Noske A., et al. Tumor-associated lymphocytes as an independent predictor of response to neo-adjuvant chemotherapy in breast cancer. J Clin Oncol (2009) 10.1200/JCO.2009.23.7370